Figma Shares Indicated To Open $105/$110
Investing.com - Teradyne (NASDAQ:TER), a semiconductor testing equipment manufacturer with a market capitalization of $16.93 billion, maintained its Overweight rating and $105.00 price target at Cantor Fitzgerald following the company’s second-quarter earnings report.
The company reported revenue of $652 million and earnings per share of $0.57, slightly exceeding consensus estimates of $650 million and $0.54, respectively. According to InvestingPro data, Teradyne maintains robust financial health with an impressive 59.36% gross profit margin and strong cash flows that sufficiently cover interest payments.
Teradyne issued third-quarter guidance below market expectations, projecting revenue of approximately $740 million and earnings per share of $0.78, compared to consensus forecasts of $761 million and $0.89.
Despite the guidance miss, Cantor Fitzgerald noted positive commentary around visibility and demand in AI-related semiconductor test markets, including compute, networking, and memory segments.
The research firm suggested Teradyne’s recent stock underperformance coupled with growth prospects into 2026 could present a "buy-the-last-cut scenario," with earnings potential closer to $5.00 per share versus bearish projections of $4.00.
In other recent news, Teradyne announced the results of its Annual Meeting, where shareholders approved an amendment to the company’s Equity and Cash Compensation Incentive Plan. This revised plan, which updates the 2006 version, incorporates several best practices in compensation governance and became effective immediately. Additionally, Teradyne appointed two new independent directors, Drew Henry and Dr. Necip Sayiner, to its Board of Directors as part of a multi-year refreshment process.
In analyst updates, UBS raised its price target for Teradyne to $630, maintaining a Buy rating, citing sustained demand and a healthy book-to-bill ratio. Meanwhile, JPMorgan downgraded the stock to Neutral, expressing concerns over potential pauses in capital spending by Teradyne’s customers. Despite this, JPMorgan increased its price target to $102.00. Furthermore, Goldman Sachs initiated coverage with a Sell rating, setting a price target of $80.00, due to Teradyne’s limited exposure to Merchant GPU Test. These developments reflect varying perspectives on Teradyne’s growth outlook and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.